摘要
目的研究强直性脊柱炎(AS)患者外周血中B淋巴细胞亚群、B细胞活化因子(BAFF)及其受体BR3的表达,为进一步探讨AS发病机制提供新的理论依据。方法采用流式细胞术测定24例AS患者及30名正常健康体检者外周血中CD19+总B细胞、CD19+CD20+CD27-初始B细胞、CD19+CD20+CD27+记忆性B细胞、CD19+CD38+抗体分泌细胞、BAFF及其受体BR3的表达百分率;采用免疫散射比浊法测定AS患者和正常体检者血清免疫球蛋白IgG、IgA、IgM浓度;并分析外周血白细胞BAFF的表达水平与B淋巴细胞亚群百分率、免疫球蛋白浓度之间的相关性。结果与正常对照组比较,AS患者的外周血中CD19+总B细胞和CD19+CD38+抗体分泌细胞的表达率、BAFF及其受体BR3的表达比例、血清IgG、IgA浓度均明显升高(P<0.05)。外周血白细胞中BAFF的表达水平分别与外周血白细胞CD19+总B细胞、CD19+CD38+抗体分泌细胞百分率及血清IgG、IgA浓度呈明显正相关(r=0.695,P=0.000;r=0.610,P=0.002;r=0.813,P=0.000;r=0.665,P=0.000)。结论 AS患者外周血中存在异常表达的总B细胞、抗体分泌细胞、BAFF及其受体BR3,提示在AS的发病过程中,B淋巴细胞的异常表达及活化可能发挥致病作用。
Objective To investigate the expressions of B lymphocyte subsets,B-cell activating factor(BAFF) and its receptor BR3 in peripheral blood from patients with ankylosing spondylitis(AS),and provide the reference for the further research of AS pathological mechanism.Methods A total of 24 AS patients and 30 healthy subjects were enrolled in the research.The expression percentages of CD19+ total B cells,CD19+CD20+CD27-native B cells,CD19+CD20+CD27+ memory B cells,CD19+CD38+ plasmablast B cells,BAFF and its receptor BR3 were determined by flow cytometry.The concentrations of serum immunological proteins(IgG,IgA and IgM) were determined by nephelometry.The correlation of BAFF expression,B lymphocyte subset percentages and immunological protein concentration was analyzed.Results The results showed that the expressions of CD19+ total B cells,CD19+CD38+ plasmablast B cells,BAFF and receptor BR3 and the concentrations of serum IgG and IgA in AS patients were significantly higher than those of healthy controls(P0.05).The expression of BAFF was correlated with the percentages of CD19+ total B cells,CD19+CD38+ plasmablast B cells,serum concentrations of IgG and IgA(r=0.695,P=0.000;r=0.610,P=0.002;r=0.813,P=0.000;r=0.665,P=0.000).Conclusions The aberrant expressions of total B cells,plasmablast B cell,BAFF and receptor BR3 may be involved in the pathogenesis of AS.
出处
《检验医学》
CAS
北大核心
2011年第12期818-822,共5页
Laboratory Medicine
基金
国家自然科学基金(30901368)
上海市青年科技启明星计划资助项目(09QA1407400)